Oligonucleotides, oligonucleotide conjugate, composition, and use
WO2026052084A1PCT designated stage Publication Date: 2026-03-12SUZHOU RIBO LIFE SCIENCE CO LTD
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-09-05
- Publication Date
- 2026-03-12
Smart Images
Figure PCTCN2025119489-FTAPPB-I100001 
Figure PCTCN2025119489-FTAPPB-I100002 
Figure PCTCN2025119489-FTAPPB-I100003
Abstract
Provided is a single-stranded oligonucleotide having a length of 16-30 nucleotides. The single-stranded oligonucleotide has sufficient complementarity with a target mRNA to mediate RNAi; and each nucleotide in the single-stranded oligonucleotide is a modified or unmodified nucleotide, wherein at least one nucleotide in the single-stranded oligonucleotide is a nucleotide X, and at least one nucleotide is a fluoro-modified nucleotide. Moreover, according to the direction from the 5' end to the 3' end, at least one nucleotide X is located after the eighth nucleotide of the single-stranded oligonucleotide and is spaced apart from the eighth nucleotide of the single-stranded oligonucleotide by 4-7 nucleotides. Provided are a double-stranded oligonucleotide comprising the single-stranded oligonucleotide as an antisense strand, an oligonucleotide conjugate, and a pharmaceutical composition.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Modified double-stranded rna agents
CN107075516A
Nucleic acid as well as composition, preparation method and application thereof
CN116497024A
Modified double stranded oligonucleotides
CN116761616A
Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
US20220049249A1
siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2
WO2023176862A1